These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16226348)

  • 1. Conformational diseases: an umbrella for various neurological disorders with an impaired ubiquitin-proteasome system.
    de Pril R; Fischer DF; van Leeuwen FW
    Neurobiol Aging; 2006 Apr; 27(4):515-23. PubMed ID: 16226348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low levels of mutant ubiquitin are degraded by the proteasome in vivo.
    van Tijn P; Verhage MC; Hobo B; van Leeuwen FW; Fischer DF
    J Neurosci Res; 2010 Aug; 88(11):2325-37. PubMed ID: 20336771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular misreading: the occurrence of frameshift proteins in different diseases.
    van Leeuwen FW; Kros JM; Kamphorst W; van Schravendijk C; de Vos RA
    Biochem Soc Trans; 2006 Nov; 34(Pt 5):738-42. PubMed ID: 17052186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain.
    Fischer DF; De Vos RA; Van Dijk R; De Vrij FM; Proper EA; Sonnemans MA; Verhage MC; Sluijs JA; Hobo B; Zouambia M; Steur EN; Kamphorst W; Hol EM; Van Leeuwen FW
    FASEB J; 2003 Nov; 17(14):2014-24. PubMed ID: 14597671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin.
    Fischer DF; van Dijk R; van Tijn P; Hobo B; Verhage MC; van der Schors RC; Li KW; van Minnen J; Hol EM; van Leeuwen FW
    Neurobiol Aging; 2009 Jun; 30(6):847-63. PubMed ID: 18760506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates.
    Verhoef LG; Heinen C; Selivanova A; Halff EF; Salomons FA; Dantuma NP
    FASEB J; 2009 Jan; 23(1):123-33. PubMed ID: 18796559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death.
    De Vrij FM; Sluijs JA; Gregori L; Fischer DF; Hermens WT; Goldgaber D; Verhaagen J; Van Leeuwen FW; Hol EM
    FASEB J; 2001 Dec; 15(14):2680-8. PubMed ID: 11726544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global changes to the ubiquitin system in Huntington's disease.
    Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
    Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system.
    Menéndez-Benito V; Verhoef LG; Masucci MG; Dantuma NP
    Hum Mol Genet; 2005 Oct; 14(19):2787-99. PubMed ID: 16103128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
    Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
    Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
    Ross CA; Pickart CM
    Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases.
    de Pril R; Fischer DF; Maat-Schieman ML; Hobo B; de Vos RA; Brunt ER; Hol EM; Roos RA; van Leeuwen FW
    Hum Mol Genet; 2004 Aug; 13(16):1803-13. PubMed ID: 15198995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new mechanism of ubiquitin-dependent proteolytic pathway--polyubiquitin chain recognition and proteasomal targeting].
    Kawahara H; Yokosawa H
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):11-5. PubMed ID: 18195523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation.
    Lindsten K; de Vrij FM; Verhoef LG; Fischer DF; van Leeuwen FW; Hol EM; Masucci MG; Dantuma NP
    J Cell Biol; 2002 Apr; 157(3):417-27. PubMed ID: 11980917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired proteasome activity and accumulation of ubiquitinated substrates in a hereditary neuropathy model.
    Fortun J; Li J; Go J; Fenstermaker A; Fletcher BS; Notterpek L
    J Neurochem; 2005 Mar; 92(6):1531-41. PubMed ID: 15748170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype.
    van Tijn P; Hol EM; van Leeuwen FW; Fischer DF
    Prog Neurobiol; 2008 Jun; 85(2):176-93. PubMed ID: 18448229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nuclear ubiquitin-proteasome system.
    von Mikecz A
    J Cell Sci; 2006 May; 119(Pt 10):1977-84. PubMed ID: 16687735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics of proteasome complexes and ubiquitinated proteins.
    Wang X; Guerrero C; Kaiser P; Huang L
    Expert Rev Proteomics; 2007 Oct; 4(5):649-65. PubMed ID: 17941820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The regulation of proteasome degradation by multi-ubiquitin chain binding proteins.
    Miller J; Gordon C
    FEBS Lett; 2005 Jun; 579(15):3224-30. PubMed ID: 15943965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.